metformin has been researched along with pexidartinib in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Amato, LB; Baldassarre, M; Bridgeman, VL; Columbaro, M; Cossarizza, A; De Luise, M; Feichtinger, RG; Foriel, S; Gasparre, G; Gibellini, L; Girolimetti, G; Grifoni, D; Iommarini, L; Kofler, B; Kurelac, I; Leone, G; Malanchi, I; Ombrato, L; Porcelli, AM; Ragazzi, M; Sollazzo, M; Umesh Ganesh, N; Vatrinet, R; Vidali, S; Vidone, M | 1 |
1 other study(ies) available for metformin and pexidartinib
Article | Year |
---|---|
Inducing cancer indolence by targeting mitochondrial Complex I is potentiated by blocking macrophage-mediated adaptive responses.
Topics: Adenoma, Oxyphilic; Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drosophila; Electron Transport Complex I; Female; Gene Knockout Techniques; HCT116 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Macrophages; Metformin; Mice; Mice, Knockout; Mice, Nude; NADH Dehydrogenase; Neovascularization, Pathologic; Pyrroles; Xenograft Model Antitumor Assays | 2019 |